» Articles » PMID: 24156513

Evolution of the Human Immunodeficiency Virus Type 2 Envelope in the First Years of Infection is Associated with the Dynamics of the Neutralizing Antibody Response

Abstract

Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4⁺ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth.

Results: CD4⁺ T cells decreased from about 50% to below 30% in both children in the first five years of infection and the infecting R5 viruses were replaced by X4 viruses within the same period. With antiretroviral therapy, viral load in child 1 decreased to undetectable levels and CD4+ T cells recovered to normal levels, which have been sustained at least until the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and death at age 9. Beginning in the first year of life, child 1 raised high titers of antibodies that neutralized primary R5 isolates more effectively than X4 isolates, both autologous and heterologous. Child 2 raised a weak X4-specific Nab response that decreased sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and positive selection, were significantly higher in the envelope of child 1 compared to child 2. Rates of R5-to-X4 tropism switch, of V1 and V3 sequence diversification, and of convergence of V3 to a β-hairpin structure were related with rate of escape from the neutralizing antibodies.

Conclusion: Our data suggests that the molecular and phenotypic evolution of the human immunodeficiency virus type 2 envelope are related with the dynamics of the neutralizing antibody response providing further support for a model in which Nabs play an important role in HIV-2 pathogenesis.

Citing Articles

An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates.

Taveira N, Figueiredo I, Calado R, Martin F, Bartolo I, Marcelino J Int J Mol Sci. 2023; 24(10).

PMID: 37240423 PMC: 10219247. DOI: 10.3390/ijms24109077.


High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients.

Bartolo I, Moranguinho I, Goncalves P, Diniz A, Borrego P, Martin F Int J Mol Sci. 2022; 23(22).

PMID: 36430777 PMC: 9695772. DOI: 10.3390/ijms232214300.


Molecular Biology and Diversification of Human Retroviruses.

Meissner M, Talledge N, Mansky L Front Virol. 2022; 2.

PMID: 35783361 PMC: 9242851. DOI: 10.3389/fviro.2022.872599.


Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2.

Serra P, Taveira N, Guedes R Int J Mol Sci. 2021; 22(4).

PMID: 33669351 PMC: 7920276. DOI: 10.3390/ijms22041948.


Evolution of HIV-1 within untreated individuals and at the population scale in Uganda.

Raghwani J, Redd A, Longosz A, Wu C, Serwadda D, Martens C PLoS Pathog. 2018; 14(7):e1007167.

PMID: 30052678 PMC: 6082572. DOI: 10.1371/journal.ppat.1007167.


References
1.
Blaak H, van der Ende M, Boers P, Schuitemaker H, Osterhaus A . In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology. 2006; 353(1):144-54. DOI: 10.1016/j.virol.2006.05.029. View

2.
Zhang H, Hoffmann F, He J, He X, Kankasa C, Ruprecht R . Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology. 2005; 2:67. PMC: 1308862. DOI: 10.1186/1742-4690-2-67. View

3.
Salazar-Gonzalez J, Bailes E, Pham K, Salazar M, Guffey M, Keele B . Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008; 82(8):3952-70. PMC: 2293010. DOI: 10.1128/JVI.02660-07. View

4.
Marcelino J, Borrego P, Nilsson C, Familia C, Barroso H, Maltez F . Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. AIDS. 2012; 26(18):2275-84. DOI: 10.1097/QAD.0b013e328359a89d. View

5.
Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C . Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology. 2004; 14(12):1229-46. DOI: 10.1093/glycob/cwh106. View